drugset
drugset / Trial / NCT03587636

Liposome Bupivacaine Interscalene Total Shoulder

NCT03587636 ↗

Phase 2 Completed 77 enrolled University of Minnesota
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Timeline

Start
2018-09-17
Primary completion
2021-03-15
Completion
2021-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 10 ml Other
Subject Bupivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.